Estradiol CypionateCAS# 313-06-4 |
- Catalpol
Catalog No.:BCN5094
CAS No.:2415-24-9
- 2-Methoxyestradiol (2-MeOE2)
Catalog No.:BCC2228
CAS No.:362-07-2
- Estradiol Benzoate
Catalog No.:BCC4779
CAS No.:50-50-0
- Ethinyl Estradiol
Catalog No.:BCC3777
CAS No.:57-63-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 313-06-4 | SDF | Download SDF |
| PubChem ID | 9403 | Appearance | Powder |
| Formula | C26H36O3 | M.Wt | 396.56 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 30 mg/mL (75.65 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate | ||
| SMILES | CC12CCC3C(C1CCC2OC(=O)CCC4CCCC4)CCC5=C3C=CC(=C5)O | ||
| Standard InChIKey | UOACKFBJUYNSLK-XRKIENNPSA-N | ||
| Standard InChI | InChI=1S/C26H36O3/c1-26-15-14-21-20-10-8-19(27)16-18(20)7-9-22(21)23(26)11-12-24(26)29-25(28)13-6-17-4-2-3-5-17/h8,10,16-17,21-24,27H,2-7,9,11-15H2,1H3/t21-,22-,23+,24+,26+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Estradiol cypionate is a 17 β-cyclopentylpropinate ester of estradiol, inhibits ET-1 synthesis via estrogen receptor
IC50 value:
Target: estrogen receptor
Estradiol cypionate is a synthetic ester, is a estrogen. Compared to other commonly used estradiol esters, via the intramuscular route, Estradiol cypionate is found to have the longest duration of action with a duration of ~11 days, References: | |||||
Estradiol Cypionate Dilution Calculator
Estradiol Cypionate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.5217 mL | 12.6084 mL | 25.2169 mL | 50.4337 mL | 63.0422 mL |
| 5 mM | 0.5043 mL | 2.5217 mL | 5.0434 mL | 10.0867 mL | 12.6084 mL |
| 10 mM | 0.2522 mL | 1.2608 mL | 2.5217 mL | 5.0434 mL | 6.3042 mL |
| 50 mM | 0.0504 mL | 0.2522 mL | 0.5043 mL | 1.0087 mL | 1.2608 mL |
| 100 mM | 0.0252 mL | 0.1261 mL | 0.2522 mL | 0.5043 mL | 0.6304 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Estradiol cypionate is the 17 β-cyclopentylpropinate ester of estradiol, which inhibits ET-1 synthesis via estrogen receptor.
- Arjunic acid
Catalog No.:BCN5229
CAS No.:31298-06-3
- LDN-27219
Catalog No.:BCC6236
CAS No.:312946-37-5
- TCS JNK 5a
Catalog No.:BCC5148
CAS No.:312917-14-9
- Raucaffricine
Catalog No.:BCN4653
CAS No.:31282-07-2
- Hygromycin B
Catalog No.:BCC1204
CAS No.:31282-04-9
- Indacaterol
Catalog No.:BCC1650
CAS No.:312753-06-3
- gamma-Mangostin
Catalog No.:BCN5228
CAS No.:31271-07-5
- THIQ
Catalog No.:BCC7539
CAS No.:312637-48-2
- SKI II
Catalog No.:BCC5029
CAS No.:312636-16-1
- Tetrahydrocannabivarin
Catalog No.:BCN6935
CAS No.:31262-37-0
- IQ 3
Catalog No.:BCC8093
CAS No.:312538-03-7
- Cimigenol-3-one
Catalog No.:BCN7430
CAS No.:31222-32-9
- Aristolochic acid A
Catalog No.:BCN6262
CAS No.:313-67-7
- ICA 121431
Catalog No.:BCC6358
CAS No.:313254-51-2
- Regadenoson
Catalog No.:BCC6438
CAS No.:313348-27-5
- Reversan
Catalog No.:BCC7764
CAS No.:313397-13-6
- VU 590 dihydrochloride
Catalog No.:BCC7803
CAS No.:313505-85-0
- T0070907
Catalog No.:BCC2261
CAS No.:313516-66-4
- INH1
Catalog No.:BCC6040
CAS No.:313553-47-8
- Bombesin
Catalog No.:BCC5708
CAS No.:31362-50-2
- PD 118057
Catalog No.:BCC7499
CAS No.:313674-97-4
- 13-Oxo-9,11-octadecadienoic acid
Catalog No.:BCC8437
CAS No.:31385-09-8
- [Des-octanoyl]-Ghrelin (human)
Catalog No.:BCC7304
CAS No.:313951-59-6
- FLI-06
Catalog No.:BCC5110
CAS No.:313967-18-9
Effect of estradiol cypionate and GnRH treatment on plasma estradiol-17beta concentrations, synchronization of ovulation and on pregnancy rates in suckled beef cows treated with FTAI-based protocols.[Pubmed:27411960]
Reprod Domest Anim. 2016 Oct;51(5):693-9.
Two experiments were conducted to evaluate the effect of different ovulation inducers on E-17beta plasma concentrations, synchronized ovulations and pregnancy rates. In Experiment 1, cows received a progesterone intravaginal device (PID) with 1 g of progesterone (P4) plus 2 mg of estradiol benzoate (EB) (day 0). At PID removal (day 8), cows received 0.150 mg of D-cloprostenol and were randomly assigned to four treatment groups (n = 10/treatment): Group ECP: 1 mg of Estradiol Cypionate at PID removal, Group EB: 1 mg of EB 24 hr after PID removal, Group GnRH: 10 mug of GnRH 48 hr after PID removal, Group ECP-GnRH: 1 mg of ECP at PID removal plus 10 mug of GnRH 48 hr later. Ultrasonographic examinations were performed to detect the dominant follicle and ovulation. GnRH-treated cows ovulated later (p < .05) compared to ECP- and ECP+GnRH-treated cows. There were effects of treatment, time and their interaction on E-17beta concentrations (p < .05). ECP treatment affected plasma E-17beta concentration, which increased earlier and decreased later compared to treatments without ECP. In Experiment 2, cows received (i) ECP: n = 126; (ii) EB: n = 126; (iii) GnRH: n = 136; (iv) ECP+GnRH: n = 139; FTAI was performed 48-50 hr after PID removal. Pregnancy rates did not differ among ovulation inducers (p > .05; ECP: 54.0%, 68/126; EB: 49.2%, 62/126; GnRH: 40.4%, 55/136; ECP+GnRH: 43.9%, 61/139). In conclusion, ECP administration (ECP and ECP+GnRH treatments) affected E-17beta concentrations, determining its earlier increase and later decrease compared to treatments without ECP (EB and GnRH treatments). ECP+GnRH-treated cows achieved the best distribution of ovulations without affecting pregnancy rates.
Progesterone-based fixed-time artificial insemination protocols for dairy cows: Gonadotropin-releasing hormone versus estradiol benzoate at initiation and estradiol cypionate versus estradiol benzoate at the end.[Pubmed:27568044]
J Dairy Sci. 2016 Nov;99(11):9227-9237.
Our objectives were to evaluate ovarian dynamics and fertility comparing 2 treatments at the start of a progesterone (P4)-based fixed-time artificial insemination (FTAI) protocol and 2 treatments at the end of the protocol. Thus, 1,035 lactating Holstein cows were assigned in a random phase of the estrous cycle to 1 of 4 treatments using a completely randomized design with a 2x2 factorial arrangement. At the beginning of the protocol (d -10), cows received GnRH or estradiol benzoate (EB) and, at the end, EB (d -1) or Estradiol Cypionate (ECP; d -2), resulting in 4 treatments: GnRH-EB, GnRH-ECP, EB-EB, and EB-ECP. All cows received an intravaginal P4 device on d -10, which was removed on d -2. Cows also received PGF2alpha on d -3 and -2. The FTAI was performed on d 0. Ovaries were evaluated by ultrasound for corpus luteum (CL) presence and regression (d -10 and -3) and follicle measurements (d -10 and 0), as well as the uterus for percentage pregnant per AI (P/AI; d 32 and 60). Blood samples were collected (d -10 and -3) for P4 measurements. Treatment with GnRH rather than EB tended to increase P/AI on d 32 (38.2 vs. 33.7%) and on d 60 (32.9 vs. 28.9%). More cows treated with GnRH had CL on d -3 compared with EB-treated cows (77.3 vs. 58.3%), due to less CL regression between d -10 and -3 (24.7 vs. 43.8%) and more cows with a new CL on d -3 (35.9 vs. 25.0%). Cows treated with GnRH also had greater P4 concentrations on d -3 than EB cows (3.4 vs. 2.0 ng/mL). Increased circulating P4 at the start of the protocol (d -10) decreased the probability of ovulation to EB or GnRH at that time. Cows from GnRH group also ovulated a larger-diameter follicle at the end of the protocol (15.5 vs. 14.7mm). No difference between EB and ECP in P/AI on d 32 (34.8 vs. 37.0) and 60 (30.8 vs. 31.0%) or in pregnancy loss (11.1 vs. 15.4%) was detected and we found no interaction between treatments for P/AI. Independent of treatment, cows with CL on d -10 and -3 had the greatest P/AI on d 60 (36.9%). In conclusion, treatments at the end of the protocol were similar for ECP or EB and we found no additive effect or interactions on P/AI between treatments. However, cows treated with GnRH rather than EB on d -10 had less luteolysis and tended to have greater P/AI, probably because P4 concentrations were greater during the protocol. Finally, regardless of treatments, cows with CL at the beginning of the protocol as well as at the time of PGF2alpha had greater fertility.
Effect of estradiol cypionate and amount of progesterone in the intravaginal device on synchronization of estrus, ovulation and on pregnancy rate in beef cows treated with FTAI based protocols.[Pubmed:24461580]
Anim Reprod Sci. 2014 Feb;145(1-2):1-7.
Three experiments were conducted to evaluate the effect of Estradiol Cypionate (ECP) and amount of progesterone in the intravaginal device (PID) on synchronization of estrus and ovulation, follicular dynamics, luteal dynamics and function and on pregnancy rate in beef cows treated with fixed-time artificial insemination (FTAI) based protocols. In Experiment 1, we evaluated the synchronization of ovulation using 1mg of ECP at PID removal (day 8 after PID insertion) or 1mg of estradiol benzoate (EB) 24h later, in cows treated with 0.558 or 1g of progesterone (P4). The final subgroups were: 0.558g+ECP: n=10; 0.558g+EB: n=11; 1g+ECP: n=10; 1g+EB: n=10. Ovarian ultrasonic examinations were performed to detect the dominant follicle and ovulation. There was no effect of treatments on the diameter of dominant follicle at any time, and on the mean interval to estrus and to ovulation (P>0.05); however, ECP treated cows had scattered distribution of estrus (P<0.03) and ovulation (P<0.03). In Experiment 2, cows received the following treatments: 0.558gP4+ECP: n=52; 0.558gP4+EB: n=52; 1gP4+ECP: n=50; 1gP4+EB: n=52; and FTAI. Pregnancy rate did not differ (P>0.05) between progesterone content (0.558g: 52.9%, 55/104; 1g: 56.9%, 58/102) but differed between estradiol esters (P<0.05; ECP: 48.9%, 49/102; EB: 61.5%, 64/104). In Experiment 3, cows received: 0.558gP4+ECP: n=55; 0.558gP4+EB: n=53; 1gP4+ECP: n=54; 1gP4+EB: n=53; and FTAI. Pregnancy rate did not differ (P>0.05) between progesterone content (0.558g: 48.1%, 52/108; 1g: 53.3%, 57/107) and estradiol esters (ECP: 47.7%, 52/109; EB: 53.8%, 57/106). In conclusion, ECP administration at device removal and progesterone content of PID has no influence on the synchronization of estrus, follicular dynamics, luteal dynamics and function. However, ECP administration affected the synchronization of ovulation and pregnancy rate in non-suckling beef cows, but did not affected pregnancy rate in suckling beef cows. Future studies should evaluate the distribution of ovulations in suckling Bos taurus beef cows.
